AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 9 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1652     ISSN: 1756-7874

Section: Licensing



After suffering development setbacks with regard to two of its late-stage drug candidates, AstraZeneca has signed separate deals with two Asian pharmaceutical companies to help bolster its sparse pipeline...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details